Biotech Values

[ghmm]

The Article from Fierce or EndPoints? I thought the Endpoints article was rather lacking in details so it could be very misleading. As an aside on 2 occasions I pointed out a couple small factual errors (on Qure Hemophilia data) and it wasn't corrected either time. I get the sense that a lot of the stories are thrown together from PR's which doesn't add a lot of value. In fairness there are some stories that are well done In general the ones on private companies seem to be better.